RxDoctor Payments Data

Michael Stillabower

Cardiovascular Disease · Newark, DENPI 1548237472

Payments from drug & device makers

What this record shows

Merit Medical Systems Inc accounts for 61.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $3,621 and has fallen 99.5% since, to $18 in 2022.

$3,833in general payments, 2019–2025

Across 95 payments — averaging $40.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$2K
  • AstraZeneca$382
  • Amgen$211
  • Boehringer Ingelheim$144
  • Amarin Pharma, Inc.$123
  • Sanofi-aventis U.S. LLC$113
  • plus $504 from 11 others
$23,994in research payments, 2019–2025

Across 2 payments — averaging $11,997 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amarin Pharma, Inc.$24K

What the payments were for

  • Travel & lodging$2,26559%
  • Food & beverage$1,56841%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,833 in reported general payments places this provider in the 60th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Other cardiovascular disease in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →